Enhanced sensitivity of A549 cells to the cytotoxic action of anticancer drugs via suppression of Nrf2 by procyanidins from Cinnamomi Cortex extract

Biochemical and Biophysical Research Communications

Volumn 413, Issue 4, 2011, Pages 623-629

  Ohnuma, Tomokazu ^a   Matsumoto, Takashi ^a   Itoi, Ayano ^a   Kawana, Ayako ^a   Nishiyama, Takahito ^a   Ogura, Kenichiro ^a   Hiratsuka, Akira ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Anticancer drugs; Cinnamomi Cortex; Lung cancer; Nrf2; Procyanidin; Sensitivity

Indexed keywords

CINNAMON EXTRACT; DOXORUBICIN; ETOPOSIDE; PROCYANIDIN DERIVATIVE; TRANSCRIPTION FACTOR NRF2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CINNAMON; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN TISSUE; LUNG CANCER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUGS, CHINESE HERBAL; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; PROANTHOCYANIDINS;

CINNAMOMI;

EID: 80053617686     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.09.014     Document Type: Article

References (26)

1. Tew K.D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994, 54:4313-4320.
2. Young L.C., Campling B.G., Cole S.P., Deeley R.G., Gerlach J.H. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin. Cancer Res. 2001, 7:1798-1804.
3. Soini Y., Näpänkangas U., Järvinen K., Kaarteenaho-Wiik R., Pääkkö P., Kinnula V.L. Expression of gamma-glutamyl cysteine synthetase in nonsmall cell lung carcinoma. Cancer 2001, 92:2911-2919.
4. Kensler T.W., Wakabayashi N., Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007, 47:89-116.
5. So H.S., Kim H.J., Lee J.H., Lee J.H., Park S.Y., Park C., Kim Y.H., Kim J.K., Lee K.M., Kim K.S., Chung S.Y., Jang W.C., Moon S.K., Chung H.T., Park R.K. Flunarizine induces Nrf2-mediated transcriptional activation of heme oxygenase-1 in protection of auditory cells from cisplatin. Cell Death Differ. 2006, 13:1763-1775.
6. Thimmulappa R.K., Mai K.H., Srisuma S., Kensler T.W., Yamamoto M., Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 2002, 62:5196-5203.
7. Hayashi A., Suzuki H., Itoh K., Yamamoto M., Sugiyama Y. Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. Biochem. Biophys. Res. Commun. 2003, 310:824-829.
8. McMahon M., Thomas N., Itoh K., Yamamoto M., Hayes J.D. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a " tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J. Biol. Chem. 2006, 281:24756-24768.
9. Kobayashi A., Kang M.I., Okawa H., Ohtsuji M., Zenke Y., Chiba T., Igarashi K., Yamamoto M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell Biol. 2004, 24:7130-7139.
10. Singh A., Misra V., Thimmulappa R.K., Lee H., Ames S., Hoque M.O., Herman J.G., Baylin S.B., Sidransky D., Gabrielson E., Brock M.V., Biswal S. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS. Med. 2006, 3:1865-1867.
11. Ohta T., Iijima K., Miyamoto M., Nakahara I., Tanaka H., Ohtsuji M., Suzuki T., Kobayashi A., Yokota J., Sakiyama T., Shibata T., Yamamoto M., Hirohashi S. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 2008, 68:1303-1309.
12. Wang X.J., Sun Z., Villeneuve N.F., Zhang S., Zhao F., Li Y., Chen W., Yi X., Zheng W., Wondrak G.T., Wong P.K., Zhang D.D. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008, 29:1235-1243.
13. Singh A., Boldin-Adamsky S., Thimmulappa R.K., Rath S.K., Ashush H., Coulter J., Blackford A., Goodman S.N., Bunz F., Watson W.H., Gabrielson E., Feinstein E., Biswal S. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 2008, 68:7975-7984.
14. Ohnuma T., Matsumoto T., Komatsu T., Nishiyama T., Ogura K., Iwata H., Hiratsuka A. Role of phase 2 drug-metabolizing enzymes modulated by extracts from 78 herbal medicines in detoxification of electrophiles and lung cancer chemotherapy. J. Trad. Med. 2010, 27:122-133.
15. Yanagida A., Murao H., Ohnishi-Kameyama M., Yamakawa Y., Shoji A., Tagashira M., Kanda T., Shindo H., Shibusawa Y. Retention behavior of oligomeric proanthocyanidins in hydrophilic interaction chromatography. J. Chromatogr. A 2007, 1143:153-161.
16. Ohnuma T., Komatsu T., Nakayama S., Nishiyama T., Ogura K., Hiratsuka A. Induction of antioxidant and phase 2 drug-metabolizing enzymes by falcarindiol isolated from Notopterygium incisum extract, which activates the Nrf2/ARE pathway, leads to cytoprotection against oxidative and electrophilic stress. Arch. Biochem. Biophys. 2009, 488:34-41.
17. Ohnuma T., Nakayama S., Anan E., Nishiyama T., Ogura K., Hiratsuka A. Activation of the Nrf2/ARE pathway via S-alkylation of cysteine 151 in the chemopreventive agent-sensor Keap1 protein by falcarindiol, a conjugated diacetylene compound. Toxicol. Appl. Pharmacol. 2010, 244:27-36.
18. Morimoto S., Nonaka G., Nishioka I. Tannins and related compounds. XXXVIII. Isolation and characterization of flavon-3-ol glucosides and procyanidin oligomers from cassia bark (Cinnamomum cassia BLUME). Chem. Pharm. Bull. 1986, 34:633-642.
19. Shoji T., Masumoto S., Moriichi N., Kanda T., Ohtake Y. Apple (Malus pumila) procyanidins fractionated according to the degree of polymerization using normal-phase chromatography and characterized by HPLC-ESI/MS and MALDI-TOF/MS. J. Chromatogr. A 2006, 1102:206-213.
20. Zhuang M., Jiang H., Suzuki Y., Li X., Xiao P., Tanaka T., Ling H., Yang B., Saitoh H., Zhang L., Qin C., Sugamura K., Hattori T. Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection. Antiviral. Res. 2009, 82:73-81.
21. Kubo M., Ma S., Wu J., Matsuda H. Anti-inflammatory activities of 70% methanolic extract from Cinnamomi Cortex. Biol. Pharm. Bull. 1996, 19:1041-1045.
22. Takahashi T., Sonobe M., Menju T., Nakayama E., Mino N., Iwakiri S., Nagai S., Sato K., Miyahara R., Okubo K., Hirata T., Date H., Wada H. Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer. J. Surg. Oncol. 2010, 101:500-506.
23. Patanasethanont D., Nagai J., Matsuura C., Fukui K., Sutthanut K., Sripanidkulchai B.O., Yumoto R., Takano M. Modulation of function of multidrug resistance associated-proteins by Kaempferia parviflora extracts and their components. Eur. J. Pharmacol. 2007, 566:67-74.
24. Puchalski R.B., Fahl W.E. Expression of recombinant glutathione S-transferase pi, Ya, or Yb1 confers resistance to alkylating agents. Proc. Natl. Acad. Sci. USA 1990, 87:2443-2447.
25. Watanabe Y., Nakajima M., Ohashi N., Kume T., Yokoi T. Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. Drug Metab. Dispos. 2003, 31:589-595.
26. Takahashi T., Kamiya T., Hasegawa A., Yokoo Y. Procyanidin oligomers selectively and intensively promote proliferation of mouse hair epithelial cells in vitro and activate hair follicle growth in vivo. J. Invest. Dermatol. 1999, 112:310-316.